527 related articles for article (PubMed ID: 22586682)
1. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Juergens RA; Wrangle J; Vendetti FP; Murphy SC; Zhao M; Coleman B; Sebree R; Rodgers K; Hooker CM; Franco N; Lee B; Tsai S; Delgado IE; Rudek MA; Belinsky SA; Herman JG; Baylin SB; Brock MV; Rudin CM
Cancer Discov; 2011 Dec; 1(7):598-607. PubMed ID: 22586682
[TBL] [Abstract][Full Text] [Related]
2. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
Connolly RM; Li H; Jankowitz RC; Zhang Z; Rudek MA; Jeter SC; Slater SA; Powers P; Wolff AC; Fetting JH; Brufsky A; Piekarz R; Ahuja N; Laird PW; Shen H; Weisenberger DJ; Cope L; Herman JG; Somlo G; Garcia AA; Jones PA; Baylin SB; Davidson NE; Zahnow CA; Stearns V
Clin Cancer Res; 2017 Jun; 23(11):2691-2701. PubMed ID: 27979916
[No Abstract] [Full Text] [Related]
3. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Azad NS; El-Khoueiry A; Yin J; Oberg AL; Flynn P; Adkins D; Sharma A; Weisenberger DJ; Brown T; Medvari P; Jones PA; Easwaran H; Kamel I; Bahary N; Kim G; Picus J; Pitot HC; Erlichman C; Donehower R; Shen H; Laird PW; Piekarz R; Baylin S; Ahuja N
Oncotarget; 2017 May; 8(21):35326-35338. PubMed ID: 28186961
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Vendetti FP; Topper M; Huang P; Dobromilskaya I; Easwaran H; Wrangle J; Baylin SB; Poirier JT; Rudin CM
Oncotarget; 2015 Jan; 6(1):56-70. PubMed ID: 25474141
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Belinsky SA; Grimes MJ; Picchi MA; Mitchell HD; Stidley CA; Tesfaigzi Y; Channell MM; Liu Y; Casero RA; Baylin SB; Reed MD; Tellez CS; March TH
Cancer Res; 2011 Jan; 71(2):454-62. PubMed ID: 21224363
[TBL] [Abstract][Full Text] [Related]
6. Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.
Weintraub K
Nat Med; 2016 Jan; 22(1):8-10. PubMed ID: 26735398
[No Abstract] [Full Text] [Related]
7. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Witta SE; Jotte RM; Konduri K; Neubauer MA; Spira AI; Ruxer RL; Varella-Garcia M; Bunn PA; Hirsch FR
J Clin Oncol; 2012 Jun; 30(18):2248-55. PubMed ID: 22508830
[TBL] [Abstract][Full Text] [Related]
8. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Tellez CS; Grimes MJ; Picchi MA; Liu Y; March TH; Reed MD; Oganesian A; Taverna P; Belinsky SA
Int J Cancer; 2014 Nov; 135(9):2223-31. PubMed ID: 24668305
[TBL] [Abstract][Full Text] [Related]
9. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
[TBL] [Abstract][Full Text] [Related]
11. A combined epigenetic therapy equals the efficacy of conventional chemotherapy in refractory advanced non-small cell lung cancer.
Rodríguez-Paredes M; Esteller M
Cancer Discov; 2011 Dec; 1(7):557-9. PubMed ID: 22586680
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
15. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
16. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Fandy TE; Herman JG; Kerns P; Jiemjit A; Sugar EA; Choi SH; Yang AS; Aucott T; Dauses T; Odchimar-Reissig R; Licht J; McConnell MJ; Nasrallah C; Kim MK; Zhang W; Sun Y; Murgo A; Espinoza-Delgado I; Oteiza K; Owoeye I; Silverman LR; Gore SD; Carraway HE
Blood; 2009 Sep; 114(13):2764-73. PubMed ID: 19546476
[TBL] [Abstract][Full Text] [Related]
17. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
18. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
20. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
